Transposons, also known as jumping genes or mobile genetic elements as they can replicate and reinsert themselves in the ...

Viruses like the one that causes COVID-19 constantly mutate, rendering many antibody treatments ineffective. A Stanford-led ...

Ocugen (NASDAQ: OCGN) Q4 2024 Earnings Call Mar 05, 2025, 8:30 a.m. ET ...

With the biohacking conference taking place in Los Angeles later this month, we wanted to take this opportunity to explore ...

Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders.

OPGx-MERTK is a gene therapy being developed by Opus Genetics to treat patients impacted by MERTK-related retinitis pigmentosa (RP). Results from a pre-clinical study which evaluated OPGx-MERTK in a ...

Q4 2024 Earnings Call Transcript March 4, 2025 Cryoport, Inc. misses on earnings expectations. Reported EPS is $-0.42 EPS, ...

Dr. Michael Wong, Roswell Park's new physician-in-chief, brings expertise in melanoma and rare skin cancers to Buffalo's ...

Hearing impairment affects millions globally, with genetics playing a major role in infant hearing loss. Early screening and ...

Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene Ansegedleucel/ALLO-501' in Relapsed/Refractory Large B-Cell ...

The "AAV Vectors in Gene Therapy - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.The Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline signifies a ...

Financially, Monopar has a cash runway until 2026 but will need additional funds for commercialization efforts. See why I'm ...